In terms of cystic fibrosis and the funding of Trikafta, I know that Pharmac has been devoting some attention to that. It is on their "options for funding" list, and in fact they've expanded the coverage. A few months ago they indicated that they would fund it, where they were able to, for those 12 years and over; they've now extended that to six years and over. I do note that they are actively considering proposals from Vertex, the pharmaceutical company that supplies Trikafta. So that is all well under way.